Shares of Corium International Inc. (NASDAQ:CORI) shot up 10.9% on Thursday . The stock traded as high as $8.33 and last traded at $7.11, with a volume of 354,258 shares changing hands. The stock had previously closed at $6.41.

Several research firms have weighed in on CORI. FBR & Co reaffirmed a “buy” rating on shares of Corium International in a report on Monday, May 2nd. Zacks Investment Research raised Corium International from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Tuesday, July 19th. Jefferies Group reissued a “buy” rating and set a $9.00 price objective on shares of Corium International in a report on Wednesday, May 11th. WBB Securities raised Corium International from a “hold” rating to a “speculative buy” rating and set a $11.00 price objective on the stock in a report on Tuesday, May 3rd. Finally, Needham & Company LLC reissued a “buy” rating and set a $15.00 price objective on shares of Corium International in a report on Thursday, June 23rd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $11.92.

The company has a 50-day moving average price of $4.53 and a 200 day moving average price of $4.35. The company’s market cap is $151.59 million.

Corium International (NASDAQ:CORI) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.08. Equities analysts predict that Corium International Inc. will post ($1.63) earnings per share for the current fiscal year.

Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.